Goldberg Ellen 4

What Happened Ellen Goldberg, a director of Castle Biosciences, was granted 11,766 restricted stock units (RSUs) on May 28, 2026. The award is recorded as a derivative acquisition at $0.00 per RSU (i.e., an equity grant rather than a purchase). Each RSU represents the right to receive one share of the company’s common stock upon vesting.

Key Details

• Transaction date: 2026-05-28 (Form 4 filed 2026-06-01).
• Transaction type/code: Grant/Award (A); 11,766 RSUs @ $0.00 (derivative).
• Shares owned after transaction: Not specified in the filing.
• Footnotes: F1 — each RSU equals one share on settlement; F2 — RSUs vest in full on the earlier of (a) the one-year anniversary (May 28, 2027) or (b) the day immediately preceding the next Annual Meeting following the grant.
• Timeliness: Filing appears timely (filed within the SEC’s 2-business-day window).

Context RSU grants are a common form of equity compensation and do not involve immediate cash payment or an open-market purchase. The award will convert into common shares only if and when the RSUs vest per the stated schedule; this filing alone does not indicate any immediate buy or sell in the market.